[HTML][HTML] Reduced lung-cancer mortality with volume CT screening in a randomized trial
…, PMA van Ooijen, JGJV Aerts… - New England journal …, 2020 - Mass Medical Soc
Background There are limited data from randomized trials regarding whether volume-based,
low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among …
low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among …
[HTML][HTML] Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
A Huber, F Dammeijer, JGJV Aerts… - Frontiers in …, 2018 - frontiersin.org
Dendritic cell (DC) based cancer immunotherapy aims at the activation of the immune system,
and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. …
and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. …
[HTML][HTML] The smell of lung disease: a review of the current status of electronic nose technology
IG Van der Sar, N Wijbenga, G Nakshbandi, J Aerts… - Respiratory …, 2021 - Springer
There is a need for timely, accurate diagnosis, and personalised management in lung
diseases. Exhaled breath reflects inflammatory and metabolic processes in the human body, …
diseases. Exhaled breath reflects inflammatory and metabolic processes in the human body, …
Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results …
…, V van der Noort, JF De Vries, JGJV Aerts… - JAMA …, 2019 - jamanetwork.com
… Dr Aerts reported receiving personal fees from Merck Sharp & Dohme, Lilly, Bristol-Myers
Squibb, Boehringer Ingelheim, Amphera, Roche, Takeda, and AstraZeneca outside the …
Squibb, Boehringer Ingelheim, Amphera, Roche, Takeda, and AstraZeneca outside the …
[HTML][HTML] Emerging treatments for malignant pleural mesothelioma: where are we heading?
Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant
neoplasm with low survival rates. In the last years we assisted to an exponential growth …
neoplasm with low survival rates. In the last years we assisted to an exponential growth …
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
…, BP Hobbs, HMU Peulen, JGJV Aerts… - The Lancet …, 2021 - thelancet.com
Background Radiotherapy might augment systemic antitumoral responses to immunotherapy.
In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-…
In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-…
[PDF][PDF] Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in …
…, N Ferrer Tur, JH Kim, MJ Ahn, JGJV Aerts… - Journal of Clinical …, 2013 - researchgate.net
Purpose Maintenance therapy is associated with improved survival in patients with non–small-cell
lung cancer (NSCLC), but few studies have compared active agents in this setting. …
lung cancer (NSCLC), but few studies have compared active agents in this setting. …
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind …
…, AJ Pelle, HC Hoogsteden, JGJV Aerts… - The Lancet …, 2014 - thelancet.com
Background Macrolide resistance is an increasing problem; there is therefore debate about
when to implement maintenance treatment with macrolides in patients with chronic …
when to implement maintenance treatment with macrolides in patients with chronic …
[HTML][HTML] COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib …
…, RW Hendriks, HC Hoogsteden, JGJV Aerts… - BMC cancer, 2010 - Springer
Background Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of
immature cells that accumulates in tumour-bearing hosts. These cells are induced by tumour-…
immature cells that accumulates in tumour-bearing hosts. These cells are induced by tumour-…
[HTML][HTML] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX …
Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …